ERBB2 and breast adenocarcinoma: Cytotoxic anti-neoplatic potency of gemcitabine-(C4-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) following an incubation period of 182-hours was very similar to gemcitabine alone after a shorter 72-hour incubation period (Figure 4).